Labopharm comments on the outcome of patent-infringement litigation related to Ultram ER
Links shared publicly online about this topic.
- 1,119total visits
Labopharm comments on the outcome of patent-infringement litigation related to Ultram ER
Labopharm Inc. today commented on the outcome of the appeal by Purdue Pharma Products L.P. and the cross-appeal by Par Pharmaceutical Companies, Inc. of the decision of the United States District Court for the District of Delaware in August 2009 on patent-infringement litigation initiated by Purdue against Par relating to Ultram ER (tramadol hydrochloride extended-release tablets).
View full resource at news-medical.net
Tags: Pharma, Analgesic Medication, Ultram, Litigation
Most Recently Shared on June 4, 2010 at 12:57 pm By:
Labopharm comments on the outcome of patent-infringement litigation related to Ultram ER: Labopharm Inc. today com... http://bit.ly/cTPJ1x
Advertisement
